There are currently 57 active clinical trials seeking participants for Atopic Dermatitis research studies. The states with the highest number of trials for Atopic Dermatitis participants are California, Florida, Texas and Ontario.
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in pediatric participants with moderate to severe AD who are candidates for systemic therapy. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug... Read More
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
08/01/2025
Locations: Applied Research Center Of Arkansas /ID# 268547, Little Rock, Arkansas +134 locations
Conditions: Atopic Dermatitis
Register for Updates
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
NCT04864886
Recruiting
Background: The immune system is the part of the body that fights infection. Some people have immune deficiencies that cause skin rashes, make them get sick often with infections, or make it difficult for their skin to heal. Researchers want to learn more to better treat conditions that affect immune response. Objective: To learn about how the immune system and skin healing are related to each other. Eligibility: People ages 18-75 with primary immune deficiency, eczema, or psoriasis. Health... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Primary Immunodeficiency, Psoriasis, Atopic Dermatitis, Immune-mediated Diseases
Register for Updates
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
NCT03936335
Recruiting
The objective of this study is to describe and compare the incidence of adverse pregnancy outcomes (spontaneous abortion/miscarriage, stillbirth) and prevalence of adverse infant outcomes (major congenital malformations \[MCMs\], small for gestational age \[SGA\]) in women with AD who are treated with dupilumab during pregnancy relative to women with AD who are not treated with dupilumab during pregnancy.
Gender:
FEMALE
Ages:
Between 18 years and 49 years
Trial Updated:
07/30/2025
Locations: Regeneron Research Site, Boston, Massachusetts
Conditions: Adverse Pregnancy Outcomes, Atopic Dermatitis
Register for Updates
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07011706
Recruiting
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/28/2025
Locations: Aclaris Study Site, Bryant, Arkansas +22 locations
Conditions: Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema
Register for Updates
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
NCT06718101
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to evaluate the clinical efficacy and safety of single therapies and/or combination therapies for moderate to severe AD through multiple substudies. This study will consist of multiple sub-studies, Sub-Study 1 will have a randomized, placebo controlled period 1 followed by a lutikizumab treatment period 2 enrolling 80 participants at a 1 to 1 ratio. In Sub-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Peak Dermatology Aesthetics and Wellness Fountain Hills /ID# 272550, Fountain Hills, Arizona +24 locations
Conditions: Atopic Dermatitis
Register for Updates
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
NCT06345404
Recruiting
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Clinical Site 5, Birmingham, Alabama +15 locations
Conditions: Atopic Dermatitis
Register for Updates
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
NCT06988605
Recruiting
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/15/2025
Locations: Galderma Investigational Site - 8893, Birmingham, Alabama +110 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
NCT07006792
Recruiting
The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/15/2025
Locations: Total Skin & Beauty Dermatology Center, PC DBA Total Dermatology, Birmingham, Alabama +74 locations
Conditions: Atopic Dermatitis
Register for Updates
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993
Recruiting
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/15/2025
Locations: Novartis Investigative Site, Birmingham, Alabama +16 locations
Conditions: Atopic Dermatitis
Register for Updates
Natural History and Genetics of Food Allergy and Related Conditions
NCT02504853
Recruiting
Background: - About 15 million Americans have a food allergy. Because there are no cures or effective prevention or treatment for food allergies, researchers want to learn more about them. Objective: - To learn more about the causes and effects of food allergy and related conditions. Eligibility: * People ages 2 99 who have food allergy and/or a related genetic or other condition * Their relatives * Healthy relatives and volunteers Design: * Participants will have at least 3 visits over 1... Read More
Gender:
ALL
Ages:
Between 1 day and 99 years
Trial Updated:
07/10/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Food Allergy, Loeys-Dietz Syndrome, Atopic Dermatitis, Eosinophilic Esophagitis
Register for Updates
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
NCT00605878
Recruiting
This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease. It will analyze healthy human skin and how the these microorganisms might change in patients with atopic dermatitis (AD), a skin condition also known as eczema. Healthy volunteers, as well as patients with moderate to severe eczema (AD), between 2 and 40 years of age may be eligible for this study. We also wish to enroll children and adults aged 2-40 who... Read More
Gender:
ALL
Ages:
Between 2 years and 100 years
Trial Updated:
07/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Atopic Dermatitis, Eczema
Register for Updates
Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)
NCT06945458
Recruiting
This is a study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered KT-621 in adult male and female patients with moderate to severe atopic dermatitis (AD).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/08/2025
Locations: Kymera Investigative Site, Birmingham, Alabama +11 locations
Conditions: Atopic Dermatitis
Register for Updates